Soleno Therapeutics (SLNO) Divestments (2016 - 2017)
Soleno Therapeutics (SLNO) posted quarterly Divestments of $717000.0 for Q3 2017, up 35750.0% year-over-year from N/an in Q3 2016, and up 23800.0% quarter-over-quarter from $3000.0 in Q2 2017.
Soleno Therapeutics (SLNO) Divestments (2016 - 2017) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Divestments for 2 consecutive years, with $717000.0 the latest figure, recorded in Q3 2017.
- In Q3 2017, Divestments rose 35750.0% year-over-year to $717000.0; the TTM figure through Dec 2017 stood at $716000.0 (changed N/A YoY), while the FY2018 annual figure was -$172000.0, down 124.02% from the prior year.
- Divestments grew to $717000.0 in Q3 2017 per SLNO's latest filing, from $3000.0 in the prior quarter.
- Across five years, Divestments topped out at $717000.0 in Q3 2017 and bottomed at -$6885.0 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 9.82 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -13.21 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 717,000.00 |
| Jun 30, 2017 | 3,000.00 |
| Mar 31, 2017 | -4,000.00 |
| Dec 31, 2016 | -6,885.00 |
| Sep 30, 2016 | 2,000.00 |